SCHEMBL3385853

SCHEMBL3385853

CCCNC(=O)c1cc(C)cc(C(=O)N(CCC)CCC)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.43
GABRG2 P18507 4/20 0.41
GABRB3 P28472 4/20 0.41
GABRA2 P47869 4/20 0.41
POLB P06746 3/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
TLR8 Q9NR97 1/20 0.37
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5415245 0.83 NTRK2 (0.39) TP53POLBTHRBRECQLTDP1
SCHEMBL3381594 0.78 TLR8 (0.38) TP53GABRG2GABRB3GABRA2POLB
SCHEMBL6685843 0.78 CHEK2 (0.39) TP53SMN1; SMN2HPGDTLR8
Hydrochloric Acid SCHEMBL6686950 0.78 CHEK2 (0.38) TP53SMN1; SMN2HPGDTLR8
SCHEMBL13634359 0.71 POLB (0.49) TP53GABRG2GABRB3GABRA2POLB
SCHEMBL1003874 0.70 POLB (0.47) TP53POLBTHRBRECQLTDP1
SCHEMBL18646131 0.69 POLB (0.46) TP53POLBTHRBRECQLTDP1
SCHEMBL6650108 0.69 L3MBTL1 (0.48) GABRG2GABRB3GABRA2POLBTHRB
SCHEMBL8320359 0.68 NTRK2 (0.51) POLBL3MBTL1SMN1; SMN2KDM4E
SCHEMBL13753819 0.67 KDM4E (0.58) HTTSMN1; SMN2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP TP53 2381/4885GABRG2 2503/4885GABRB3 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.